Sanuwave Health Q2 Earnings Call Highlights

2 weeks ago 6

MarketBeat

Fri, August 7, 2026 astatine 10:04 AM CDT 6 min read

Key Points

Interested successful Sanuwave Health Inc.? Here are 5 stocks we similar better.
Second-quarter gross fell 3% twelvemonth implicit twelvemonth to $9.7 million, arsenic a 34% diminution successful UltraMIST strategy income offset continued maturation successful recurring applicator revenue. Applicator units roseate 27% twelvemonth implicit year, portion progressive systems accrued to 1,411 from 1,382 successful the archetypal quarter.
Profitability weakened arsenic gross borderline fell to 76.2%, the institution posted a $0.7 cardinal nett nonaccomplishment versus prior-year income of $0.6 million, and adjusted EBITDA declined to $1.2 cardinal from $3.2 million. Used UltraMIST instrumentality from wound-care supplier closures pressured caller strategy sales.
Sanuwave withdrew its 2026 gross guidance due to the fact that of uncertainty surrounding projected CMS reimbursement changes. The institution estimates physician-office reimbursement could diminution from astir $397 presently to $316 successful 2027 if the connection is finalized, portion infirmary outpatient reimbursement could emergence 14%.

3 Lesser-Known Healthcare Names With Major Upside successful Store

Sanuwave Health (NASDAQ:SNWV) reported second-quarter 2026 gross of $9.7 million, down 3% from $10.1 cardinal a twelvemonth earlier, arsenic little UltraMIST strategy income offset continued maturation successful the company's recurring applicator business.

Chairman and Chief Executive Officer Morgan Frank said applicator income remained beardown passim the quarter, with portion measurement rising 13% sequentially from the anterior grounds acceptable successful the archetypal 4th and 27% twelvemonth implicit year. Applicator gross accrued 8% sequentially and 13% twelvemonth implicit year, surpassing the company's anterior quarterly gross grounds acceptable successful the 3rd 4th of 2025.

→ Meta's Earnings Drop Shows Wall Street Wants More Than Ad Growth

Frank said the quality betwixt maturation successful applicator portion measurement and gross reflected a greater premix of reseller sales, successful which products are sold astatine wholesale prices. He characterized applicator show arsenic broadly successful enactment with the company's plans and arsenic an denotation of lawsuit assurance successful UltraMIST contempt disruption among wound-care providers.

Used Systems Pressure Capital Sales

The company's capital-equipment income were affected by the availability of utilized UltraMIST devices pursuing closures among wound-care providers. Frank said the marketplace disruption followed changes to Medicare reimbursement for tegument substitutes and reimbursement clawbacks, which person enactment fiscal unit connected practitioners that utilized some UltraMIST and Allograft.

→ 4 Oil and Gas ETF Plays arsenic Prices Stay Sky-High

UltraMIST strategy gross fell astir 34% twelvemonth implicit twelvemonth to $2.3 cardinal from $3.4 million. Frank said the institution estimates that utilized systems whitethorn person accounted for 40 to 60 strategy income during the quarter, though helium cautioned that the estimation is hard to measurement precisely.

Read Entire Article